Cargando…

Identification of RNPC3 as a novel JAK2 fusion partner gene in B‐acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib

BACKGROUND: Hematopoietic neoplasms with chromosomal translocations involving JAK2 are rare, and most of them show myeloproliferative neoplasm‐associated features, followed by B‐acute lymphoblastic leukemia (B‐ALL). De novo B‐ALL cases with JAK2 rearrangements are suggested to be appropriately consi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xue, Wang, Fang, Zhang, Yang, Ma, Xiaoli, Liu, Mingyue, Cao, Panxiang, Zhou, Lin, Wang, Lan, Zhang, Xian, Wang, Tong, Liu, Hongxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057088/ https://www.ncbi.nlm.nih.gov/pubmed/31885183 http://dx.doi.org/10.1002/mgg3.1110

Ejemplares similares

Next‐generation sequencing reveals the presence of DDX41 mutations in acute lymphoblastic leukemia and aplastic anemia
por: Zhang, Yang, et al.
Publicado: (2021)

Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
por: FAN, Birao, et al.
Publicado: (2022)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

P346: DECIPHER STRUCTURAL ABERRATIONS OF THE PAX5 GENE AND THEIR CORRELATION WITH DIAGNOSTIC CLASSIFICATION AND TREATMENT OUTCOME IN B CELL LYMPHOBLASTIC LEUKEMIA
por: Wang, Tong, et al.
Publicado: (2023)

A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide
por: Chen, Xue, et al.
Publicado: (2019)

Identification of STRBP as a Novel JAK2 Fusion Partner Gene in a Young Adult With Philadelphia Chromosome-Like B-Lymphoblastic Leukemia
por: Zhang, Xin-Yue, et al.
Publicado: (2021)

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
por: Van Den Neste, Eric, et al.
Publicado: (2018)

PB1775: TRANSPOSABLE ELEMENT PARTICIPATES IN COMPOSING STAT3::RARA::LTR40A-RC TRINARY FUSION IN VARIANT ACUTE PROMYELOCYTIC LEUKEMIA AND CONFERS ATRA RESISTANCE VIA LIGAND BINDING DOMAIN TRUNCATION
por: Chen, Xue, et al.
Publicado: (2023)

PB1786: TRINARY FUSION AND LIGAND BINDING DOMAIN TRUNCATION AS RECURRENT AND CRUCIAL MOLECULAR CHARACTERISTICS IN RARG-DRIVEN ACUTE PROMYELOCYTIC LEUKEMIA AND RENDER UNRESPONSIVE TO ALL-TRANS RETINOIC ACID
por: Zhou, Xiaosu, et al.
Publicado: (2023)

hnRNPC Promotes Malignancy in Pancreatic Cancer through Stabilization of IQGAP3
por: Yang, Nannan, et al.
Publicado: (2022)

Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia
por: Verbeke, Delphine, et al.
Publicado: (2019)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Response to growth hormone in patients with RNPC3 mutations
por: Martos‐Moreno, Gabriel Á, et al.
Publicado: (2018)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center
por: Chen, Xue, et al.
Publicado: (2021)

hnRNPC regulates cancer-specific alternative cleavage and polyadenylation profiles
por: Fischl, Harry, et al.
Publicado: (2019)

Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia
por: Rizzuto, Giuliana, et al.
Publicado: (2022)

Gene mutation spectrum of patients with myelodysplastic syndrome and progression to acute myeloid leukemia
por: Liu, Ming, et al.
Publicado: (2021)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Overexpression of hnRNPC2 induces multinucleation by repression of Aurora B in hepatocellular carcinoma cells
por: SUN, DA-QUAN, et al.
Publicado: (2013)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Pathogenic Variants in RNPC3 are Associated with Hypopituitarism and Primary Ovarian Insufficiency
por: Akin, Leyla, et al.
Publicado: (2022)

Case Report: Whole genome sequencing identifies CCDC88C as a novel JAK2 fusion partner in pediatric T-cell acute lymphoblastic leukemia
por: Krstic, Aleksandra, et al.
Publicado: (2023)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)

The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes
por: Griveau, Audrey, et al.
Publicado: (2020)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022)

Regulation of Mdm2 mRNA Stability by RNA-binding Protein RNPC1
por: Zhang, Jin, et al.
Publicado: (2013)

RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer
por: Xue, Jin-Qiu, et al.
Publicado: (2014)

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020)

Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis
por: Li, Xia, et al.
Publicado: (2021)

Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL
por: Jaramillo, Sonia, et al.
Publicado: (2020)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
por: Pope, Eleanor, et al.
Publicado: (2022)

Expanding the phenotype of biallelic RNPC3 variants associated with growth hormone deficiency
por: Verberne, Eline A., et al.
Publicado: (2020)

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
por: Shide, K, et al.
Publicado: (2017)

The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice
por: Shaker, Mohamed E., et al.
Publicado: (2022)

Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera: A case report
por: Al-Mashdali, Abdulrahman F., et al.
Publicado: (2021)

BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia
por: Tsuzuki, Shinobu, et al.
Publicado: (2022)

Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2(V617F)-myeloproliferative neoplasm
por: Fukutsuka, Katsuhiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4adkcapqv0tbl1hobgsmnpc6gh